Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy
Abstract Background PRECONNECT was an international, phase IIIb trial evaluating the safety and efficacy of trifluridine/tipiracil (FTD/TPI) for metastatic colorectal cancer (mCRC). Methods Patients with mCRC received FTD/TPI 35 mg/m2 twice-daily on days 1–5 and 8–12 of each 28-day cycle for third-...
| Published in: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Online Access: | https://doi.org/10.1186/s12885-022-10489-4 |